Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Related Concept Videos

Pharmacokinetics in Geriatric Patients: Effect of Age on Drug Absorption01:22

Pharmacokinetics in Geriatric Patients: Effect of Age on Drug Absorption

765
As individuals age, their body's physiology evolves, affecting drug pharmacokinetics. The most apparent changes occur in the gastrointestinal tract, where an increase in gastric pH, a delay in gastric emptying, and a reduction in gastrointestinal motility are observed. Remarkably, these changes do not substantially modify the absorption of orally administered drugs, particularly those absorbed via passive diffusion.Transdermal drug delivery emerges as a highly viable method for older adults due...
765
Pharmacokinetics in Geriatric Patients: Effect of Age on Drug Excretion01:18

Pharmacokinetics in Geriatric Patients: Effect of Age on Drug Excretion

288
In geriatric patients, renal physiology undergoes significant changes, including diminished renal blood flow and a lower glomerular filtration rate (GFR), leading to alterations in medication clearance. Drugs such as aminoglycoside antibiotics, lithium, and digoxin, which rely on glomerular filtration for removal from the body, particularly impact pharmacokinetics. These drugs tend to have slower clearance rates in older adults, necessitating careful dosage considerations.Evaluation of renal...
288
Pharmacokinetics in Geriatric Patients: Effect of Age on Drug Metabolism01:18

Pharmacokinetics in Geriatric Patients: Effect of Age on Drug Metabolism

273
Geriatric patients show significant variation in how their bodies process medications, which can change how effective and safe treatments are. The liver is the primary organ where drug metabolism occurs, involving two main types of chemical reactions: phase I and II. Phase I metabolism is driven by the cytochrome P450 enzyme system, which includes key types such as CYP3A, CYP2D6, and CYP2C9. Research indicates that while aging doesn't notably alter the levels or activity of these enzymes, it...
273
Pharmacodynamics in Geriatric Patients: Effects of Age01:27

Pharmacodynamics in Geriatric Patients: Effects of Age

284
Age-related pharmacokinetic changes are extensively documented, but understanding age-related pharmacodynamic alterations is relatively limited. This knowledge gap can be partly attributed to the complexity of developing appropriate measures of drug responses compared to bioanalytical methods for determining drug concentrations.Most information regarding age-related differences in human pharmacodynamics originates from cross-sectional studies. However, these studies assume that observed mean...
284
Glucose Homeostasis: Regulation of Blood Glucose01:02

Glucose Homeostasis: Regulation of Blood Glucose

4.7K
Carbohydrates consumed through foods are converted into glucose, a crucial energy source for the body. In the prandial state, high blood glucose levels stimulate the secretion of insulin from the pancreas. Insulin inhibits hepatic glucose production and stimulates glucose uptake and metabolism by muscle and adipose tissue. The excess glucose is converted into glycogen and stored in the liver and muscles.
During fasting, when blood glucose levels are low, the pancreas secretes glucagon. it...
4.7K
The Effect of Aging on Tissues01:19

The Effect of Aging on Tissues

4.0K
Several body functions deteriorate with age. The external signs of aging are easily identifiable. For example, the skin becomes dry, less elastic, and thins out, forming wrinkles. The skin of the face begins to appear looser due to a decrease in the levels of elastic and collagen fibers in the connective tissue. Additionally, melanin production in the hair follicle decreases with age, resulting in gray hair. Moreover, the senses of sight and hearing decline, so glasses and hearing aids may...
4.0K

You might also read

Related Articles

Articles linked to this work by shared authors, journal, and citation graph.

Sort by
Same author

Protocol for automated analysis of oil red O-stained Caenorhabditis elegans using Redwormpix, a Python-based application.

STAR protocols·2026
Same author

Neuronal lipid droplets play a conserved and sex-biased role in maintaining whole-body energy homeostasis.

Nature metabolism·2026
Same author

Characterization of a C9orf72 Knockout Danio rerio model for ALS and cross-species validation of potential therapeutics screened in Caenorhabditis elegans.

PloS one·2026
Same author

Dataset reporting the differential effect of <i>HNRNPA1</i> isoforms on alternative splicing.

Data in brief·2026
Same author

TDP-43 pathology is linked to motor neuron loss and is independent of stress granules <i>in vivo</i>.

bioRxiv : the preprint server for biology·2026
Same author

Repurposing the HMG-CoA Reductase Inhibitor Atorvastatin for SRD5A3-CDG.

bioRxiv : the preprint server for biology·2026

Related Experiment Video

Updated: Feb 27, 2026

Quantifying Tissue-Specific Proteostatic Decline in Caenorhabditis elegans
09:18

Quantifying Tissue-Specific Proteostatic Decline in Caenorhabditis elegans

Published on: September 7, 2021

3.3K

Glucose delays age-dependent proteotoxicity.

Arnaud Tauffenberger1, Alexandra Vaccaro, Anais Aulas

  • 1CRCHUM, Université de Montréal, Montréal, Québec, Canada.

Aging Cell
|June 28, 2012
PubMed
Summary
This summary is machine-generated.

Glucose enrichment delays neurodegeneration in model organisms by reducing toxic protein misfolding. This finding highlights a potential metabolic intervention for age-dependent pathologies and extends lifespan.

More Related Videos

Measuring Glucose Uptake in Drosophila Models of TDP-43 Proteinopathy
07:07

Measuring Glucose Uptake in Drosophila Models of TDP-43 Proteinopathy

Published on: August 3, 2021

3.2K
Monitoring of Ubiquitin-proteasome Activity in Living Cells Using a Degron dgn-destabilized Green Fluorescent Protein GFP-based Reporter Protein
10:25

Monitoring of Ubiquitin-proteasome Activity in Living Cells Using a Degron dgn-destabilized Green Fluorescent Protein GFP-based Reporter Protein

Published on: November 10, 2012

17.3K

Related Experiment Videos

Last Updated: Feb 27, 2026

Quantifying Tissue-Specific Proteostatic Decline in Caenorhabditis elegans
09:18

Quantifying Tissue-Specific Proteostatic Decline in Caenorhabditis elegans

Published on: September 7, 2021

3.3K
Measuring Glucose Uptake in Drosophila Models of TDP-43 Proteinopathy
07:07

Measuring Glucose Uptake in Drosophila Models of TDP-43 Proteinopathy

Published on: August 3, 2021

3.2K
Monitoring of Ubiquitin-proteasome Activity in Living Cells Using a Degron dgn-destabilized Green Fluorescent Protein GFP-based Reporter Protein
10:25

Monitoring of Ubiquitin-proteasome Activity in Living Cells Using a Degron dgn-destabilized Green Fluorescent Protein GFP-based Reporter Protein

Published on: November 10, 2012

17.3K

Area of Science:

  • Neuroscience
  • Metabolism Research
  • Aging Biology

Background:

  • Nutrient availability significantly impacts organismal lifespan and metabolism.
  • Glucose metabolism is a key factor in healthy aging and age-related diseases.
  • While glucose restriction extends lifespan in simple organisms, its role in neuroprotection is less understood.

Purpose of the Study:

  • To investigate the effect of glucose enrichment on neurodegenerative models.
  • To determine if glucose enrichment can mitigate proteotoxicity associated with neurodegeneration.
  • To explore the link between metabolic state and protein misfolding in aging.

Main Methods:

  • Utilized Caenorhabditis elegans models of neurodegeneration.
  • Introduced genetic mutations associated with polyglutamine, TDP-43, FUS, and amyloid-beta.
  • Administered glucose enrichment to assess protective effects against proteotoxicity.

Main Results:

  • Glucose enrichment significantly delayed toxicity in multiple neurodegeneration models.
  • Observed a reduction in protein misfolding as a mechanism of protection.
  • Demonstrated broad protective effects of glucose enrichment against proteotoxicity.

Conclusions:

  • Glucose enrichment offers a protective effect against proteotoxicity in models of neurodegeneration.
  • Metabolic interventions, specifically glucose modulation, may represent a therapeutic strategy for age-related neurodegenerative diseases.
  • Reducing protein misfolding through metabolic means is a viable approach to combat age-dependent pathologies.